Hópital Pitié Salpétriere, Paris — France
The development of fotemustine in its various indications, on more than 1 800 treated patients, and in studies conducted throughout Europe since 1985, is presented below:
These data confirm:
- the activity of fotemustine in disseminated malignant melanoma, either as monochemotherapy (16.4—47 % response rate (RR)) or in combination with dacarbazine or vindesine.
- the interest of the drug in gliomas: either recurrent (RR = 26.3 %) or inoperable (RR = 29 % when combined with radiotherapy)
- the benefit in NSC lung cancer with a RR close to 20 % in relapses of conventional first line chemotherapy.
Studies are ongoing in various indications (kidney, colon, IA route, cervix, ovary) and available results will be presented.
